^18F—FDG PET—CT显像在淋巴瘤疗效评价中的应用  

^18F-FDG PET-CT imaging for treatment evaluation in lyrnphoma

作　　者：闫瑾[1] 杨建伟[1] 李鹏[1] 

机构地区：[1]河南省肿瘤医院PET—CT中心,郑州450003

出　　处：《白血病．淋巴瘤》2009年第10期622-623,629,共3页Journal of Leukemia & Lymphoma

摘　　要：目的研究PET-CT对淋巴瘤治疗后评估的临床价值。方法40例经治疗的淋巴瘤患者行^18F—FDGPET—CT显像，其中5例于治疗前后多次显像，评价其疗效，与临床疗效评价作对比。结果5例患者行多次显像，其中2例治疗后病灶消失，2例缓解，1例肿瘤复发，皆与临床相符。35例患者治疗后行PET—CT显像，30例临床疗效为完全缓解和部分缓解的患者中，PET-CT显像阳性者25例；5例临床确认有肿瘤复发或明显残余，PET—CT显像均为阳性，PET—CT显像后改变了进一步临床治疗方案。结论^18F—FDGPET—CT显像能灵敏、准确地检出淋巴瘤复发及残余病灶，对疗效评价及指导临床治疗有重要价值。Objective To investigate the clinical value of PET-CT scans in lymphomatous patients in post-therapy evaluation. Methods ^18 F-FDG PET-CT imaging were performed in 40 lymphomatous patients whom had been received therapy. Successive PET-CT imaging were performed in 5 cases, and the treatment was evaluated with clinical evaluation. Results Successive PET-CT imaging were performed in 5 cases, in which the tumor was eradicated in 2 cases, improved in 2 cases, and relapsed in 1 case. In 35 patients PET-CT imaging was repeated after treatment, among them 30 cases with complete or partial remission, and PET-CT imaging was positive in 25 cases. PET-CT imaging was still positive in 8 eases with recurrent or remnant tumor. PET-CT imaging changed the therapeutic regime. Conclusion PET-CT imaging can detect the recurrent or remnant tumor sensitively and accurately. There is a significant value for the guidance of clinical therapeutic.

关 键 词：淋巴瘤 放射性核素显像 评价研究 

分 类 号：R733.1[医药卫生—肿瘤]